
.png)
COVID-19 Evidence Reviews
as of 10/4/22

latest update date
|
select |
|
---|---|---|
11/1/21
|
Hartmann-Boyce J, Rees K, Perring JC, et al. | Diabetes Care
Aim: To review the evidence regarding the extent to which PWD are at increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or of suffering its complications, including associated mortality. WHO COLLABORATIVE
CLINICAL CHARACTERISTICS
|
|
6/1/21
|
Chou R, Dana T, Buckley D, et al. | Ann Intern Med
Aim: To examine the burden of SARS-CoV-2, SARS-CoV-1, and Middle Eastern respiratory syndrome (MERS)-CoV on HCWs and risk factors for infection, using rapid and living review methods. UPDATED WHO COLLABORATIVE
|
|
4/27/21
|
Mackey K, Kansagara D, Vela K | Ann Intern Med
Aim: To synthesize evidence on the role of ACE inhibitor and ARB use on patient outcomes in COVID-19 as well as evidence on the benefits and harms of initiating these medications to treat patients with COVID-19. UPDATED WHO COLLABORATIVE VA ESP
|
|
3/26/21
|
Burns J, Movsisyan A, Stratil JM, et al. | Cochrane Database Syst Rev
Aim: To assess the effectiveness of travel?related control measures during the COVID?19 pandemic on infectious disease and screening?related outcomes. UPDATED WHO COLLABORATIVE
INFECTION CONTROL
|
|
3/23/21
|
Ryan RE, Parkhill A, Schonfeld L, et al. | Health Evidence Network
Aim: To analyse evidence regarding communication with individuals and communities within the wider structural and sociopolitical context of the pandemic to support public health decision-makers when planning and implementing physical distancing measures. WHO COLLABORATIVE
|
|
1/19/21
|
von Philipsborn P, Biallas R, Burns J, et al. | BMJ Open
Aim: To assess the effects of prior and current use of NSAIDs in patients with acute viral respiratory infections on acute severe adverse events , on acute healthcare utilization, as well as on quality of life and long-term survival. WHO COLLABORATIVE
|
|
9/18/20
|
WHO REACT Working Group | JAMA
Aim: To estimate the association between administration of corticosteroids compared with usual care or placebo and 28-day all-cause mortality. WHO COLLABORATIVE
CANDIDATE THERAPEUTICS
|
|
9/14/20
|
Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. | Cochrane Database of Systematic Reviews
Aim: To assess the effects of quarantine (alone or in combination with other measures) of individuals who had contact with confirmed cases of COVID19, who travelled from countries with a declared outbreak, or who live in regions with high transmission of the disease. UPDATED WHO COLLABORATIVE
INFECTION CONTROL
|
|
6/17/20
|
Agarwal A, Basmaji J, Muttalib F, et al. | Can J Anaesth
Aim: To describe the efficacy and safety of HFNC in acute hypoxemic respiratory failure; and to determine the risk of dispersion, aerosol generation and associated transmission of COVID-19 with HFNC. UPDATED WHO COLLABORATIVE
|
|
5/14/20
|
Yaacoub S, Schunemann H, Khabasa J, et al. | BMJ Global Health
Aim: To systematically review the literature to scope and assess the effects of specific strategies for the management of the bodies. UPDATED WHO COLLABORATIVE
|
|
4/30/20
|
| Cochrane COVID Rapid Reviews
WHO COLLABORATIVE
|
|
4/27/20
|
Halpin D, Singh D, Hadfield RM | Eur Respir J
Aim: To evaluate whether pre-morbid use or continued administration of inhaled steroids is a risk factor for adverse outcomes in acute respiratory infections due to COVID-19, SARS or MERS. WHO COLLABORATIVE
CANDIDATE THERAPEUTICS
|
|
4/19/20
|
| WHO
Aim: To assess the effects of prior and current use of NSAIDs in patients with acute viral respiratory infections on acute severe adverse events , on acute health care utilization, as well as on quality of life and long-term survival. WHO COLLABORATIVE
|
|
4/16/20
|
Ford N, Vitoria M, Rangaraj A, et al. | J Int AIDS Soc
Aim: To systematically review the clinical outcomes of using antiretroviral drugs for the prevention and treatment of coronaviruses and planned clinical trials. WHO COLLABORATIVE
CANDIDATE THERAPEUTICS
|
|
4/15/20
|
What is the efficacy and acceptability of universal mask use by health care workers in health care settings in preventing respiratory infection during epidemics?
![]() Chou R, Dana T | Pacific Northwest Evidence-Based Practice Center
Aim: To inform evidence based guidance on universal mask use by HCWs in health care settings during the COVID-19 pandemic. WHO COLLABORATIVE
|
|
4/6/20
|
Devane D | Cochrane COVID Rapid Reviews
WHO COLLABORATIVE
|
|
4/6/20
|
Vandvik PO | Cochrane COVID Rapid Reviews
WHO COLLABORATIVE
|
|
4/6/20
|
Chou R | Cochrane COVID Rapid Reviews
WHO COLLABORATIVE
|
|
4/6/20
|
Reveiz L | Cochrane COVID Rapid Reviews
WHO COLLABORATIVE
|
|
4/6/20
|
Reveiz L | Cochrane COVID Rapid Reviews
WHO COLLABORATIVE
|
|
4/6/20
|
Reveiz L | Cochrane COVID Rapid Reviews
WHO COLLABORATIVE
|
|
4/6/20
|
Reveiz L | PAHO
WHO COLLABORATIVE
|
|
4/5/20
|
Physical distance from a known COVID-19 patient and droplet transmission; with and without mask use
![]() Akl E, Schunemann H | American University of Beirut Medical Center (protocol under development)
WHO COLLABORATIVE
|
|
4/4/20
|
Corticosteroids in patients with COVID-19, SARS, MERS, influenza, community acquired pneumonia, or ARDS
![]() Ye Z, Guyatt G | McMaster University
WHO COLLABORATIVE
|
|
4/1/20
|
| Centre for Health Communication and Participation
WHO COLLABORATIVE
|
|
3/26/20
|
Quarantine: Individual and community for influenza
![]() Gartlehner G | Danube University (protocol under development)
WHO COLLABORATIVE
|
|
3/25/20
|
| Centre for Health Communication and Participation
WHO COLLABORATIVE
|
|
Noninvasive ventilation as an aerosol generating procedures
![]() Schunemann H | McMaster University
WHO COLLABORATIVE
|